Sensus HealthcareSRTS +2.36%75 Days Payable is 152.56 as of Mar. 2026, which is 30% above its 10-year median of 117.30. GuruFocus rates SRTS with a GF Score™ of 75/100 and a GF Value™ of $2.85 (Fairly Valued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sensus Healthcare ranks better than 74.21% on this metric.
The historical rank and industry rank for Sensus Healthcare's Days Payable or its related term are showing as below:
SRTS'
s Days Payable Range Over the Past 10 Years
Min: 79.86 Med: 117.3 Max: 147.32
Current: 128.3
During the past 13 years, Sensus Healthcare's highest Days Payable was 147.32. The lowest was 79.86. And the median was 117.30.
SRTS's Days Payable is ranked better than 74.21% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs SRTS: 128.30
Sensus Healthcare's Days Payable
increased
from Mar. 2025 (119.45) to Mar. 2026 (152.56).
It may suggest that Sensus Healthcaredelayed paying its suppliers.
Sensus Healthcare Days Payable Related Terms
Sensus Healthcare Days Payable Historical Data
* Premium members only.
The historical data trend for Sensus Healthcare's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sensus Healthcare's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensus Healthcare Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's Days Payable distribution charts can be found below:
* The bar in red indicates where Sensus Healthcare's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sensus Healthcare's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensus Healthcare (SRTS) has a Days Payable of 152.56 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sensus Healthcare and its competitors. This is 30% above median its historical median of 117.30. Over the past decade, Sensus Healthcare's Days Payable has ranged from 79.86 to 147.32. According to the industry distribution chart, Sensus Healthcare ranks #205 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 25.8%.
Is Sensus Healthcare's Days Payable too high?
Sensus Healthcare's current Days Payable of 152.56 is 30% above median its 10-year median of 117.30. Over the past 10 years, this metric has ranged from a low of 79.86 to a high of 147.32. The Medical Devices & Instruments industry median Days Payable is 67.87. Sensus Healthcare's value of 152.56 is 124.8% above this industry median. Based on the distribution chart, Sensus Healthcare ranks #205 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sensus Healthcare has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's Days Payable compare to ELUT and COCH?
According to the Medical Devices & Instruments industry distribution chart, Sensus Healthcare ranks #205 out of 795 companies for Days Payable. This puts Sensus Healthcare in the upper half of its industry. The industry median Days Payable is 67.87. Sensus Healthcare's value of 152.56 is 124.8% above this benchmark. Historically, Sensus Healthcare's own Days Payable has ranged from 79.86 to 147.32 over the past decade. While the company's 10-year median is 117.30 vs. the industry median of 67.87, Sensus Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sensus Healthcare's current Days Payable of 152.56 is 124.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sensus Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sensus Healthcare's current Days Payable is 152.56, which is 30% above median its own 10-year median of 117.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Fairly Valued. The stock's GF Value™ is $2.85, compared to a current price of $3.04 — trading 6.7% above its estimated fair value. The current Days Payable is 152.56, which is 30% above median its 10-year median of 117.30 and 124.8% above the Medical Devices & Instruments industry median of 67.87. Sensus Healthcare's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current Days Payable is 152.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensus Healthcare (SRTS) Overvalued in 2026?
Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued.
The current stock price of $3.04 is trading 6.7% above its estimated GF Value™ of $2.85.
GuruFocus considers Sensus Healthcare to be Fairly Valued.
Key valuation signals for SRTS:
Days Payable: 152.56 (30% above median its 10-year median of 117.30)
GF Value™: $2.85 vs. price of $3.04 (6.7% above fair value)
Industry Position: 124.8% above the Medical Devices & Instruments median (#205 of 795)
No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
75GF Score
Get the complete analysis for SRTS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTS has been successfully added to your 
